Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What do you think the value of the company is at this point? What would be the correct stock price to reflect the valuation?
QTMM is green. Just letting you know.
Check the QTMM twitter feed. They just posted about a counterfeit Toyota parts supplier getting busted.
$QTMM
0.038 - strong close.
Limoncello, per favore.
I see. So all that ice melting, record high temperatures, storms stronger now than anything ever recorded before, massive fires, and the increasing CO2 concentration as clearly demonstrated by the Keeling Curve - Nope, none of this is happening. It’s all a hoax, all in your head, everything is fine, la la la...
Stop denying reality already. We’re in big trouble. Denying it won’t make it go away. Stop making science political to justify denial. Sheesh.
Looks like it's headed straight for Mar-A-Lago. They should be fine, because climate change is a big hoax.
Oh, I know. Completely.
I voted no, against the R/S
I have to agree. The only direction for QTMM is up.
ALWAYS BE CLOSING
Please do not reverse split, sir. Doing so will decimate shareholders. A buyback is a much, much better decision.
It is absurd. I agree completely. It should be removed and re-written. DVLP is a growing company that's making money. The fundamentals are solid.
$$$DVLP$$$
Form D filed.
He could offer a better product at a cheaper price. Nanosys has quite an overhead to pay.
If the dpi resolution is high enough, medical will definitely use QD displays. I used to work in radiology. Resolution is everything.
QMC is only going to get bigger from here. Yes, it will take time. Yes, there will be delays. Nevertheless, the slope is going UP in a POSITIVE direction due to GROWTH. This is like a Seurat painting. You have to step away from the little details to see the big picture.
$$QTMM$$
I don't think you can when on the mobile site. The mobile site is a stripped-down version of the desktop site. I prefer the mobile site for this reason, but when I am on my laptop I will have a tab open to the iHub streamer so I don't have to check my phone. The desktop site has everything.
When you log onto iHub on a desktop or laptop computer, (NOT the mobile site) click on "streamer" for your stocks. Look for DVLP, and click on where it says "Golden Developing Solutions" to the right of the DVLP ticker letters. On the next page, click on "Boards", and it will take you to the header that is above the message boards. The header is what I am talking about.
https://investorshub.advfn.com/boards/board.aspx?board_id=9683
NEWS!!
https://www.globenewswire.com/news-release/2019/07/22/1885712/0/en/Results-of-Single-Center-Study-on-Delcath-s-PHP-Therapy-Published-in-Cancer-Imaging.html
—————————
Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging
Retrospective Study by University Hospital of Tubingen Shows Median Overall Survival of 27.4 Months in Patients with Ocular Melanoma Liver Metastases
July 22, 2019 08:00 ET | Source: Delcath Systems, Inc.
NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a single-institution retrospective study conducted by University Hospital of Tubingen (UHT) in Germany on the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases were published in the journal Cancer Imaging.
The study, Chemosaturation with percutaneous hepatic perfusion of melphalan for liver dominant metastatic uveal melanoma: a single center experience, by Dr. Christoph Artzner, et al, evaluated the safety and efficacy of PHP® Therapy in 16 patients with unresectable liver metastases from ocular melanoma treated with CHEMOSAT between June 2015 and December 2018. Tumor response was evaluated following each PHP treatment using Response Evaluation Criteria in Solid Tumors (RECIST), and serious adverse events (SAEs) were evaluated using Common Criteria for Adverse Events (CTCAE).
The 16 patients underwent a total of 28 PHP treatments. Results of the study in the 15 evaluable patients showed that after the first PHP treatment, nine patients (60%) had a partial response (PR), five patients (33%) stable disease, and one patient (7%) had progressive disease for an initial disease control rate of 93%. Median progression free survival (PFS) after the first treatment was 11.1 months. Six patients received a second PHP treatment, three patients received three treatments, and a single patient received six treatments. Median overall survival (OS) was 27.4 months.
Safety analysis showed that grade three SAEs were observed in 14% of treatments, and these were anemia, leukopenia and thrombocytopenia. The sole grade four SAE observed was in one patient who suffered a cardiac arrest during the first PHP treatment and was removed from the study. Subsequent evaluation discovered this patient had coronary artery occlusion which was successfully treated. Retrospective evaluation of this patient’s pre-procedure imaging reveal signs of coronary artery disease, and investigators subsequently modified their screening procedures for cardiovascular risk factors. Investigators stated that most SAEs were grade one or two and that 5% of the reported grade three and four SAEs required additional intervention.
Investigators concluded that for patients with liver-dominant metastatic uveal melanoma, treatment with PHP Therapy had “observed rates for OS and PFS that exceeded the reported outcomes for traditional systemic treatment.” Investigators stated that SAEs were frequent, but most did not require additional intervention, and that care should be taken in patients with suspected coronary heart disease.
The Ignore button is a wonderful feature, IMO.
$DVLP$
Hear hear. Yes. Share buyback would be most excellent.
You’re welcome. Now your website, sir. I think could use a little help. I’d love to see a “Gallery” of pictures of the new facility.
WOW. How much for a house there? I may want to relocate.
I think India is going to be where it’s at in the coming decades. China & trade are becoming odd bedfellows, IMO.
I was drawn to the doom and gloom statements about the company’s viability. Maybe they are just doing some c.y.a. ?
I may be totally wrong. Your input is valued, truly.
Not good.
This board is good for company news and updates, for the most part.
Does DVLP have anything to do with DNAX?
Look at the big picture: New factory, revenue, a changing world environment that will favor this technology. There is every reason to believe in QTMM.
What does INKW have to do with DVLP ?
I agree completely. This is a speculative growth stock. I see a real company with superb technology, and I see many more reasons for success than failure. BUT, it will take time. This is a long play here. Not for flippers.
I don’t see this anywhere on the Insider Financial post about DVLP. I’m on their mailing list.
It’s just shorts playing their games. I see bargain prices here.
8K out
Hear say. That article does not pass the smell test.
Probably uplisting.
This is why I’m holding. Yeah, their finances are in the toilet. But Delcath is far from over.